Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 129 Carcinoma, Renal Cell 36 Parkinson Disease 4, Autosomal Dominant Lewy Body 31 Neoplasms 27 Cholangiocarcinoma 23 Endometrial Neoplasms 19 Liver Neoplasms 16 Melanoma 15 Thyroid Neoplasms 13 Stomach Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Biliary Tract Neoplasms 12 Neoplasm Metastasis 9 Squamous Cell Carcinoma of Head and Neck 8 Recurrence 8 Ovarian Neoplasms 8 Breast Neoplasms 8 Uterine Cervical Neoplasms 7 Triple Negative Breast Neoplasms 5 Thyroid Carcinoma, Anaplastic 5 Small Cell Lung Carcinoma 5 Neuroendocrine Tumors 5 Esophageal Squamous Cell Carcinoma 5 Colorectal Neoplasms 5 Pancreatic Neoplasms 4 Kidney Neoplasms 4 Carcinoma, Transitional Cell 4 Adenocarcinoma 4 Thyroid Cancer, Papillary 3 Solid Tumors 3

Interventions

Doxorubicin 25 Gemcitabine 16 Trabectedin 12 Ifosfamide 12 Radiotherapy 11 Docetaxel 10 Dacarbazine 8 pazopanib 7 Nivolumab 6 Specimen Handling 5 liposomal doxorubicin 4 Temozolomide 4 Biopsy 4 pembrolizumab 3 Sunitinib 3 Sorafenib 3 Radiation 3 Magnetic Resonance Spectroscopy 3 Filgrastim 3 rucaparib 2 pegfilgrastim 2 olaratumab 2 eribulin 2 durvalumab 2 cixutumumab 2 cemiplimab 2 brostallicin 2 belinostat 2 avelumab 2 X-Rays 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Leiomyosarcoma × lenvatinib × Clear all

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡